Previous 10 | Next 10 |
NEWTON, Mass. , Sept. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fireside ch...
NEWTON, Mass. , Aug. 31, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Christy J. Oliger to its Board of Directors. Ms. Oliger is the former Senior Vi...
Deals and Financings Antengene, a three-year old Shanghai startup originally backed by Celgene, will conduct a Hong Kong IPO that is expected to raise $200 million (see story ). Focused on oncology, Antengene has 12 projects in its portfolio, a mix of in-licensed drugs and in-house R&D ...
Our analysis concludes the share prices of oncology-related companies are down, on average, 25% from peaking the third week of June 2020. With the exception of Agenus Inc. ( AGEN ), that appears to be trading higher on anticipation its vaccine adjuvant will be used in 2 or more of the eventual...
NEWTON, Mass. , Aug. 21, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, congratulates its founder, President and Chief Scientific Officer, Sharon Shacham , PhD, MBA, for being selected as ...
Image source: The Motley Fool. Karyopharm Therapeutics Inc (NASDAQ: KPTI) Q2 2020 Earnings Call Aug 4, 2020 , 8:30 a.m. ET Operator Continue reading
Karyopharm Therapeutics, Inc. (KPTI) Q2 2020 Earnings Conference Call August 04, 2020, 08:30 ET Company Participants Ian Karp - VP, Investor & Public Relations Michael Kauffman - Co-Founder, CEO & Director John Demaree - Chief Commercial Officer Michael Mason - SVP, CFO...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2020 Q2 earnings Read more ...
NEWTON, Mass. , Aug. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2020 . In addition, Karyopharm highlighted select corpora...
NEWTON, Mass. , July 28, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on Tuesday, August 4, 2020 . Karyopharm's management team will host a confe...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...